Commonwealth Coat of Arms of Australia

 

PB 80 of 2025

 

National Health (Pharmaceutical Benefits Scheme - Exempt items - Section 84AH) Amendment Determination (No. 1) 2025

I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.

Dated         26 June 2025 

REBECCA RICHARDSON

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health, Disability and Ageing

 

 

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule — Amendments

National Health (Pharmaceutical Benefits Scheme–Exempt items – Section 84AH) Determination 2017 (PB 81 of 2017)

 

 

  This instrument is the National Health (Pharmaceutical Benefits Scheme-Exempt items - Section 84AH) Amendment Determination (No. 1) 2025.

  This instrument may also be cited as PB 80 of 2025.

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 July 2025.

 

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

  This instrument is made under section 84AH of the National Health Act 1953.

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

 

      

  1.   In the Schedule, after the entry for Metronidazole Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL  

             Omit:

 

Naproxen

Oral suspension 125 mg per 5mL, 474 mL

Oral